Neoleukin therapeutics, inc. (AQXP)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Revenue (Note 9)

-

-

-

-

-

-

-

25,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses
Research and development (Note 6)

5,498

-

-

-

104

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development (Note 7)

-

-

1,420

-1,995

-

-

10,713

17,996

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquired in-process research and development (Note 3)

-

-

47,716

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

-

-

-

-

-

-

-

-

10,508

-

8,456

10,475

5,777

8,132

6,134

9,235

4,881

3,926

3,687

3,619

4,567

6,325

5,323

4,551

1,880

2,751

3,027

1,247

572

General and administrative (Note 6)

3,573

3,468

10,380

2,423

2,555

2,728

4,484

4,314

4,309

4,973

3,614

3,520

2,745

3,331

2,149

1,830

1,953

1,666

1,230

1,173

1,472

1,493

987

1,081

735

593

389

369

423

Total operating expenses

9,071

8,356

59,516

428

2,659

5,300

15,197

22,310

14,817

16,532

12,070

13,995

8,522

11,463

8,283

11,065

6,834

5,592

4,917

4,792

6,039

7,818

6,310

5,632

2,615

3,345

3,417

1,616

996

Loss from operations

-

-

-59,516

-428

-

-

-15,197

2,690

-

-

-12,070

-13,995

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income, net
Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

Sale of equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

29

Change in fair value of derivative liabilities (Note 6(a))

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

29

14

914

-

24

947

-

Amortization and extinguishment of remaining discount on preferred shares upon conversion of preferred shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,884

-

120

119

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7

2

2

454

-

1

1

1

Other income, net (Note 11)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

164

123

-71

-118

42

-373

677

-1

196

-189

-

-

-

-

Other income (expenses)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

142

-21

-

Amortization and extinguishment of remaining discount on preferred shares upon conversion of preferred shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

25

Foreign exchange loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-17

Other income, net (Note 7)

429

255

384

427

451

413

204

228

194

264

237

229

206

-

137

-

-

-

-

-

-

-273

26

208

-1,613

-194

44

805

-13

Net loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6,711

-

-5,035

-4,750

-6,412

-

-6,284

-5,424

-4,228

-3,539

-3,372

-811

-1,010

Income tax recovery (Note 10)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5

0

-

Net loss

-8,642

-8,101

-59,132

-1

-2,208

-4,887

-14,993

2,918

-14,623

-16,268

-11,833

-13,766

-8,316

-11,244

-8,146

-10,901

-6,711

-5,663

-5,035

-4,750

-6,412

-8,091

-6,284

-5,424

-4,228

-

-3,367

-811

-

Basic

-

-

-

-

-

-

-

0.12

-

-

-

-0.59

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted

-

-

-

-

-

-

-

0.12

-

-

-

-0.59

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic

-

-

-

23,537

-

-

-

23,521

-

-

-

23,444

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted

-

-

-

23,537

-

-

-

23,846

-

-

-

23,444

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion for liquidation preference on preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,397

1,157

Accretion for share issuance costs on preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

42

44

Tax expense on preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

130

346

Total loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,382

-2,558

Net loss per common stock - basic and diluted (Note 8)

-0.18

-

-2.26

-

-0.09

-

-0.64

-

-0.62

-

-0.50

-

-0.36

-0.48

-0.46

-0.63

-0.39

-0.26

-0.43

-0.44

-0.60

-0.37

-0.59

-0.51

-1.28

-17.51

-15.64

-7.89

-8.48

Basic and diluted weighted average number of common stock outstanding (Note 8)

49,168

-

26,185

-

23,537

-

23,537

-

23,480

-

23,464

-

23,423,150

23,459

17,690

17,212

17,211

17,274

11,841

10,723

10,711

10,150

10,695

10,675

3,148

301

301

301

301

Comprehensive loss:
Net loss

-8,642

-8,101

-59,132

-1

-2,208

-4,887

-14,993

2,918

-14,623

-16,268

-11,833

-13,766

-8,316

-11,244

-8,146

-10,901

-6,711

-5,663

-5,035

-4,750

-6,412

-8,091

-6,284

-5,424

-4,228

-

-3,367

-811

-

Other comprehensive income—unrealized gain on available-for-sale securities

-

-

-

-

-

0

2

22

46

33

102

0

-36

-161

-80

119

243

-293

-1

1

7

-

6

1

-

-

-

-

-

Comprehensive loss

-8,642

-8,101

-59,132

-1

-2,208

-4,887

-14,991

2,940

-14,577

-16,235

-11,731

-13,766

-8,352

-11,405

-8,226

-10,782

-6,468

-5,956

-5,036

-4,749

-6,405

-8,102

-6,278

-5,423

-4,228

-3,539

-3,367

-811

-1,010